The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Program to Accelerate Clinical Trials.
Since 1998, ADDF has provided more than $29 million in funding for early stage clinical drug trials for Alzheimer's disease and related dementias. To help propel novel drugs into the clinic, ADDF also has provided over $6.5 million in support of final preclinical studies required by regulatory agencies for the initiation of clinical research studies.
The goal of the foundation's PACT program is to increase the number of innovative treatments tested in humans for Alzheimer's disease and related dementias. To that end, the program will fund clinical trials through Phase 2a of novel drug candidates, including small molecules and biologics (antibodies, oligonucleotides, peptides, gene therapies, cell therapies); proof-of-concept biomarker-based trials in patients for repurposed/repositioned drugs; and regulatory studies for investigational new drug (IND)/clinical trial application preclinical packages that are required before testing novel drugs in human subjects.
Proposed molecular targets will be evaluated based on the strength of available evidence linking the target to the disease and demonstrating that modulating its biological activity will improve symptoms or modify disease progression. Current target areas of interest include but are not limited to neuroprotection, inflammation, vascular function, mitochondria and metabolic function, proteostasis, ApoE, epigenetics, and synaptic activity and neurotransmitters.
Up to $3 million will be awarded based on stage and scope of the research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Funding is open to researchers, clinicians, and postdoctoral fellows working in an academic medical center, university, nonprofit, or biotechnology company who are able to demonstrate a clear need for nonprofit funding. Funding is provided through mission-related investments that require return on investment based on scientific and/or business milestones.
Letters of Intent must be received no later than April 13. Upon review, selected applicants will be invited to submit a full proposal by May 11, 2018.
For complete program guidelines and application instructions, see the Alzheimer's Drug Discovery Foundation website.